Table 1 BclI, ER22/23EK, and N363S genotype in patients with Crohn's disease (CD), ulcerative colitis (UC), and controls.

	Genotype (n (%))			OR (95% CI)
	Wild‐type	Heterozygous	Mutated	Mutated v not mutated	p Value
BclI
Controls (n = 70)	30 (42.9%)	34 (48.5%)	6 (8.6%)	–	–
CD (n = 34)	9 (26.5%)	16 (47%)	9 (26.5%)	3.84 (1.23–11.91)	0.03
UC (n = 23)	10 (43.5%)	12 (52.2%)	1 (4.3%)	1.03 (0.39–2.65)	1
ER22/23EK	Wild‐type	Heterozygous	Mutated	Heterozygous v wild‐type
Controls (n = 70)	67 (95.7%)	3 (4.3%)	0 (0%)	–	–
CD (n = 34)	32 (94.1%)	2 (5.9%)	0 (0%)	1.39 (0.22–8.78)	0.6
UC (n = 23)	22 (95.7%)	1 (4.3%)	0 (0%)	1.01 (0.10–10.27)	1
N363S	Wild‐type	Heterozygous	Mutated	Heterozygous v wild‐type
Controls (n = 70)	67 (95.7%)	3 (4.3%)	0 (0%)	–	–
CD (n = 34)	33 (97.1%)	1 (2.9%)	0 (0%)	0.68 (0.07–6.76)	1
UC (n = 23)	21 (91.3%)	2 (8.7%)	0 (0%)	2.13(0.33–13.60)	0.6

OR (95% CI), odds ratio (95% confidence interval).